Hyperlipidemia in APOE2 transgenic mice is ameliorated by a truncated apoE variant lacking the C-terminal domain

Journal of Lipid Research

Volumn 44, Issue 2, 2003, Pages 408-414

  Gerritsen, Gery ^a   Kypreos, Kyriakos E ^a   Van der Zee, André ^a   Teusink, Bas ^b   Zannis, Vassilis I ^c   Havekes, Louis M ^a,b   Van Dijk, Ko Willems ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TNO   (Netherlands)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenovirus mediated gene transfer; Apolipoprotein E; Familial dysbetalipoproteinemia; Hypertriglyceridemia

Indexed keywords

ADENOVIRUS VECTOR; APOLIPOPROTEIN E2; APOLIPOPROTEIN E4; CHYLOMICRON; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; GENE TRANSFER; GENETIC ANALYSIS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 3; HYPERTRIGLYCERIDEMIA; LIPID TRANSPORT; LIPOLYSIS; MOUSE; NONHUMAN; PENETRANCE; PRIORITY JOURNAL; PROTEIN DOMAIN; TRANSGENIC MOUSE;

ADENOVIRIDAE; ANIMALS; APOLIPOPROTEIN E2; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; CHOLESTEROL; HUMANS; HYPERLIPIDEMIAS; LIPIDS; LIPOPROTEINS; LIPOPROTEINS, VLDL; LIVER; MICE; MICE, TRANSGENIC; PROTEIN ISOFORMS; PROTEIN STRUCTURE, TERTIARY; TRIGLYCERIDES;

EID: 0142060177     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1194/jlr.M200313-JLR200     Document Type: Article

References (26)

1. Mahley, R. W., and Z. S. Ji. 1999. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J. Lipid Res. 40: 1-16.
2. Jong, M. C., V. E. Dahlmans, M. H. Hofker, and L. M. Havekes. 1997. Nascent very-low-density lipoprotein triacylglycerol hydrolysis by lipoprotein lipase is inhibited by apolipoprotein E in a dose-dependent manner. Biochem. J. 328: 745-750.
3. de Beer, F., K. W. van Dijk, M. C. Jong, L. C. van Vark, A. van der Zee, M. H. Hofker, F. J. Fallaux, R. C. Hoeben, A. H. Smelt, and L. M. Havekes. 2000. Apolipoprotein E2 (Lys146→Gln) causes hypertriglyceridemia due to an apolipoprotein E variant-specific inhibition of lipolysis of very low density lipoproteins-triglycerides. Arterioscler. Thromb. Vasc. Biol. 20: 1800-1806.
4. Rensen, P. C. N., and T. J. C. van Berkel. 1996. Apolipoprotein E effectively inhibits lipoprotein lipase-mediated lipolysis of chylomicron-like triglyceride-rich lipid emulsions in vitro and in vivo. J. Biol. Chem. 271: 14791-14799.
5. Huang, Y., X. Q. Liu, S. C. Rall, Jr., and R. W. Mahley. 1998. Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglyceride-rich lipoproteins. J. Biol. Chem. 273: 17483-17490.
6. Kuipers, F., M. C. Jong, Y. Lin, M. Eck, R. Havinga, V. Bloks, H. J. Verkade, M. H. Hofker, H. Moshage, T. J. Berkel, R. J. Vonk, and L. M. Havekes. 1997. Impaired secretion of very low density lipoprotein-triglycerides by apolipoprotein E-deficient mouse hepatocytes. J. Clin. Invest. 100: 2915-2922.
7. Mensenkamp, A. R., M. C. Jong, H. van Goor, M. J. van Luyn, V. Bloks, R. Havinga, P. J. Voshol, M. H. Hofker, K. W. van Dijk, L. M. Havekes, and F. Kuipers. 1999. Apolipoprotein E participates in the regulation of very low density lipoprotein-triglyceride secretion by the liver. J. Biol. Chem. 274: 35711-35718.
8. Brewer, H. B., Jr., L. A. Zech, R. E. Gregg, D. Schwartz, and E. J. Schaefer. 1983. NIH conference. Type III hyperlipoproteinemia: diagnosis, molecular defects, pathology, and treatment. Ann. Intern. Med. 98: 623-640.
9. Breslow, J. L., V. I. Zannis, T. R. SanGiacomo, J. L. Third, T. Tracy, and C. J. Glueck. 1982. Studies of familial type III hyperlipoproteinemia using as a genetic marker the apoE phenotype E2/2. J. Lipid Res. 23: 1224-1235.
10. Zannis, V. I., and J. L. Breslow. 1981. Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification. Biochemistry. 20: 1033-1041.
11. Weisgraber, K. H., T. L. Innerarity, and R. W. Mahley. 1982. Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J. Biol. Chem. 257: 2518-2521.
12. Maugeais, C., U. J. Tietge, K. Tsukamoto, J. M. Glick, and D. J. Rader. 2000. Hepatic apolipoprotein E expression promotes very low density lipoprotein-apolipoprotein B production in vivo in mice. J. Lipid Res. 41: 1673-1679.
13. Tsukamoto, K., P. Smith, J. M. Glick, and D. J. Rader. 1997. Liver-directed gene transfer and prolonged expression of three major human ApoE isoforms in ApoE-deficient mice. J. Clin. Invest. 100: 107-114.
14. Kypreos, K. E., K. W. van Dijk, A. van Der Zee, L. M. Havekes, and V. I. Zannis. 2001. Domains of apolipoprotein E contributing to triglyceride and cholesterol homeostasis in vivo. Carboxyl-terminal region 203-299 promotes hepatic very low density lipoprotein-triglyceride secretion. J. Biol. Chem. 276: 19778-19786.
15. Tsukamoto, K., C. Maugeais, J. M. Glick, and D. J. Rader. 2000. Markedly increased secretion of VLDL triglycerides induced by gene transfer of apolipoprotein E isoforms in apoE-deficient mice. J. Lipid Res. 41: 253-259.
16. van Dijk, K. W., B. J. van Vlijmen, H. B. van't Hof, A. van der Zee, S. Santamarina-Fojo, T. J. van Berkel, L. M. Havekes, M. H. Hofker. 1999. In LDL receptor-deficient mice, catabolism of remnant lipoproteins requires a high level of apoE but is inhibited by excess apoE. J. Lipid Res. 40: 336-344.
17. van Vlijmen, B. J. K. W. van Dijk, H. B. van't Hof, P. J. van Gorp, A. van der Zee, H. van der Boom, M. L. Breuer, M. H. Hofker, L. M. Havekes. 1996. In the absence of endogenous mouse apolipoprotein E, apolipoprotein E*2(Arg-158 → Cys) transgenic mice develop more severe hyperlipoproteinemia than apolipoprotein E*3-Leiden transgenic mice. J. Biol. Chem. 271: 30595-30602.
18. Tao, N., G. P. Gao, M. Parr, J. Johnston, T. Baradet, J. M. Wilson, J. Barsoum, and S. E. Fawell. 2001. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol. Ther. 3: 28-35.
19. van Vlijmen, B. J., H. B. van 't Hof, M. J. Mol, H. van der Boom, A. van der Zee, R. R. Frants, M. H. Hofker, and L. M. Havekes. 1996. Modulation of very low density lipoprotein production and clearance contributes to age- and gender-dependent hyperlipoproteinemia in apolipoprotein E3-Leiden transgenic mice. J. Clin. Invest. 97: 1184-1192.
20. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 249: 5133-5162.
21. Teusink, B., A. R. Mensenkamp, H. van der Boom, F. Kuipers, K. W. van Dijk, and L. M. Havekes. 2001. Stimulation of the in vivo production of very low density lipoproteins by apolipoprotein E is independent of the presence of the low density lipoprotein receptor. J. Biol. Chem. 276: 40693-40697.
22. Mensenkamp, A. R., L. M. Havekes, J. A. Romijn, and F. Kuipers. 2001. Hepatic steatosis and very low density lipoprotein secretion: the involvement of apolipoprotein E. J. Hepatol. 35: 816-822.
23. Yoshida, H., A. H. Hasty, A. S. Major, H. Ishiguro, Y. R. Su, L. A. Gleaves, V. R. Babaev, M. F. Linton, S. Fazio. 2001. Isoform-specific effects of apolipoprotein E on atherogenesis: gene transduction studies in mice. Circulation. 104: 2820-2825.
24. Saito, H., P. Dhanasekaran, F. Baldwin, K. H. Weisgraber, S. Lund-Katz, and M. C. Phillips. 2001. Lipid binding-induced conformational change in human apolipoprotein E. Evidence for two lipid-bound states on spherical particles. J. Biol. Chem. 276: 40949-40954.
25. Rensen, P. C., N. Herijgers, M. H. Netscher, S. C. Meskers, M. van Eck, and T. J. van Berkel. 1997. Particle size determines the specificity of apolipoprotein E-containing triglyceride-rich emulsions for the LDL receptor versus hepatic remnant receptor in vivo. J. Lipid Res. 38: 1070-1084.
26. Saito, H., K. Okuhira, N. Tsuchimoto, A. Vertut-Doi, C. Matsumoto, T. Tanimoto, S. Okada, and T. Handa. 2001. Modulation of apolipoprotein E-mediated plasma clearance and cell uptake of emulsion particles by cholesteryl ester. Lipids. 36: 27-33.